Acumen Pharmaceuticals (ABOS) Operating Leases (2022 - 2024)
Acumen Pharmaceuticals recorded quarterly Operating Leases of $185000.0 in Q3 2024, down 15.53% quarter-over-quarter from $219000.0 in Q2 2024.
Acumen Pharmaceuticals' Operating Leases history runs 3 years deep, the most recent figure standing at $185000.0 for Q3 2024.
- In Q3 2024, Operating Leases changed N/A year-over-year to $185000.0; the TTM figure through Sep 2024 stood at $185000.0 (changed N/A YoY), while the FY2023 annual figure was $284000.0, changed N/A from the prior year.
- Operating Leases came in at $185000.0 for Q3 2024 at Acumen Pharmaceuticals, down from $219000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $284000.0 in Q4 2023 to a low of $62000.0 in Q1 2022.
- A 3-year average of $186000.0 and a median of $185000.0 in 2024 frame the typical range for Operating Leases.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 185,000.00 |
| Jun 30, 2024 | 219,000.00 |
| Mar 31, 2024 | 252,000.00 |
| Dec 31, 2023 | 284,000.00 |
| Sep 30, 2022 | 133,000.00 |
| Jun 30, 2022 | 167,000.00 |
| Mar 31, 2022 | 62,000.00 |